CDER’s new proposal to withdraw the accelerated approval of Makena (HPC) was dependent on a significant randomized demo that failed to substantiate the benefit of this drug to newborns or cut down the risk of PTB. In building the choice to suggest Makena’s withdrawal, click here CDER also reviewed outcomes from prior experiments of progestins